39,152 Shares in Biogen Inc. $BIIB Bought by First Citizens Bank & Trust Co.

Key Points

• First Citizens Bank & Trust Co. acquired 39,152 Biogen shares worth approximately $8.84 million, while other institutions—including BlackRock—also increased or initiated positions. Institutional investors now own 87.93% of Biogen’s stock.
• Analyst sentiment is broadly positive, with several firms raising price targets and MarketBeat reporting a “Moderate Buy” consensus with a $236.04 target. JPMorgan upgraded the stock to Overweight and cited potential catalysts from Biogen’s immunology pipeline, including litifilimab and felzartamab.
• Biogen shares opened at $228.90, near their 12-month high, but investors face near-term earnings risk: third-quarter EPS is expected to decline sharply year over year ahead of the company’s October 28 report.

First Citizens Bank & Trust Co. acquired a new position in Biogen Inc. (NASDAQ:BIIB - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 39,152 shares of the biotechnology company's stock, valued at approximately $8,844,000.

Other institutional investors also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Biogen in the second quarter worth about $3,453,878,000. Orbimed Advisors LLC bought a new stake in shares of Biogen in the 1st quarter valued at about $11,293,000. Nippon Life Global Investors Americas Inc. purchased a new stake in Biogen during the 2nd quarter valued at about $29,648,000. Handelsbanken Fonder AB boosted its holdings in Biogen by 12.7% during the 2nd quarter. Handelsbanken Fonder AB now owns 93,236 shares of the biotechnology company's stock valued at $20,145,000 after acquiring an additional 10,510 shares during the period. Finally, Tidal Investments LLC boosted its holdings in Biogen by 9.0% during the 2nd quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company's stock valued at $13,794,000 after acquiring an additional 5,256 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: JPMorgan upgraded Biogen to Overweight from Neutral and raised its price target to $300 from $210. The firm cited an increasingly compelling catalyst path, including expected 2027 clinical readouts for felzartamab and litifilimab. The target implies meaningful upside from recent trading levels. JPMorgan upgrade and price target article
• Positive Sentiment: Litifilimab’s 52-week Phase 2 data in cutaneous lupus erythematosus supported the company’s immunology pipeline. The AMETHYST study showed sustained improvements in skin disease activity and a generally well-tolerated safety profile. FDA Breakthrough Therapy designation further strengthens the drug’s potential, although additional development remains necessary. Litifilimab 52-week data article
• Neutral Sentiment: Citi maintained a Hold rating on Biogen. The stance provides a counterweight to JPMorgan’s upgrade and suggests some analysts believe the recent rally and pipeline optimism may already be reflected in the shares. Citi maintains Hold rating article
• Negative Sentiment: Biogen’s upcoming third-quarter results are expected to show a sharp double-digit EPS decline. This earnings risk is limiting the impact of the bullish pipeline news ahead of the company’s scheduled October 28 report. Biogen quarterly earnings preview article

Analysts Set New Price Targets

A number of equities analysts have commented on BIIB shares. Guggenheim lifted their price target on Biogen from $260.00 to $280.00 and gave the stock a "buy" rating in a research note on Tuesday, July 21st. UBS Group raised their target price on shares of Biogen from $240.00 to $270.00 and gave the stock a "buy" rating in a report on Friday. Needham & Company LLC raised their price target on shares of Biogen from $255.00 to $256.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Seaport Research Partners raised Biogen to an "outperform" rating in a research report on Monday. Finally, Truist Financial raised shares of Biogen from a "hold" rating to a "buy" rating and raised their target price for the stock from $190.00 to $235.00 in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Biogen presently has an average rating of "Moderate Buy" and a consensus price target of $236.04.

Biogen Stock Down 0.2%

Shares of NASDAQ:BIIB opened at $228.90 on Wednesday. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The stock has a fifty day simple moving average of $218.37 and a two-hundred day simple moving average of $203.00. Biogen Inc. has a 12-month low of $138.00 and a 12-month high of $238.24. The stock has a market capitalization of $33.82 billion, a price-to-earnings ratio of 16.42, a PEG ratio of 2.53 and a beta of 0.09.

Biogen (NASDAQ:BIIB - Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping analysts' consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The firm had revenue of $2.74 billion for the quarter, compared to analysts' expectations of $2.46 billion. During the same period in the prior year, the firm posted $5.47 earnings per share. The company's quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, research analysts anticipate that Biogen Inc. will post 12.41 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen's products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich's ataxia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.